• Skip to primary navigation
  • Skip to content
  • Skip to footer
Gynesonics

Gynesonics

Advancing technology. Improving women's lives.

  • Our Company
    • About Us
    • Careers
    • Compliance
  • Our People
    • Management
    • Board of Directors
    • Investors
  • Our Technology
    • The Sonata System
    • Indications and Safety
    • Instructions for Use
    • Request for Medical or Scientific Information
  • Our News
    • Press Releases
    • In the News
    • Publications
    • 2022 Events
  • Contact Us

Gynesonics Announces Anthem, the Second Largest Healthcare Payer in the U.S., Issues Medical Necessity Coverage for the Treatment of Symptomatic Uterine Fibroids with the Sonata Procedure

September 14, 2021 by tmurphy

 Anthem’s decision significantly increases nationwide access for Sonata

Redwood City, CA, September 14, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced Anthem, Inc., the largest managed health care company in the Blue Cross Blue Shield Association, has provided positive payer coverage for the Sonata® Treatment.  Anthem’s decision creates access for this minimally invasive procedure for women across the country, having the largest impact in California, New York, Georgia, Ohio, Virginia and Indiana.  The Sonata technology platform integrates the first and only commercial intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, providing an incision-free, uterus-preserving, transcervical treatment for symptomatic uterine fibroids.  The Sonata Treatment is an alternative to hysterectomy and myomectomy, and can treat a wide range of fibroid types, sizes and locations.  Fibroids are treated from inside the uterus, so the Sonata Treatment requires no incisions, no tissue is surgically removed, and the uterus is preserved.

Anthem is one of the country’s largest healthcare insurance plans and this policy validates the need for less invasive treatment options for women with systematic fibroids.  Currently in the U.S. women will wait 3-5 years for treatment trying to avoid invasive surgery.  As well, black women have the highest incidence of fibroid diagnoses, yet studies show they are least likely to be offered less invasive treatment options. 1,2

“We hope this coverage policy helps ensure access to all women seeking less invasive treatments,” said Kelly Petrucci, Global VP of Strategy and Market Access for Gynesonics.  “At Gynesonics, we are committed to delivering solutions to patients, physicians and health insurers that combine safety, efficacy and economic benefits, positively impacting the entire healthcare system.”

In the SONATA clinical trial, 95 percent of patients experienced a reduction in menstrual bleeding by 12 months.  Additionally, 50 percent of women return to normal activities the next day.  The overall impact of treatment with Sonata was significant for these women, with 97 percent of women at 12 months indicating they would recommend the procedure.  Women were followed in the study long-term which demonstrated durable symptom relief for three years.2

“The positive coverage decision from Anthem supports the rapid acceleration and acceptance of the Sonata treatment.  This follows the recent inclusion of Sonata by ACOG in the fibroid treatment Practice Bulletin as well as the 2021 European Consensus publication recommending a new fibroid treatment algorithm with the Sonata technology at the forefront,” said Chris Owens, President and CEO of Gynesonics.  “These important policies and clinical recommendations further advance our commitment to ensuring patient and physician access, engagement, and education for the Sonata technology.”

For more information about the Sonata System, please visit https://gynesonics.com/us/sonata-system/.

References

  1. https://www.anthem.com/dam/medpolicies/abcbs/active/policies/mp_pw_a053391.html
  2. https://gynesonics.com/us/publications/

About Sonata System

The Sonata System uses radiofrequency energy to ablate fibroids under real time sonography guidance from within the uterine cavity, utilizing the first and only intrauterine ultrasound transducer.  The system includes a proprietary graphical user interface (SMART Guide), enabling the operator to target fibroids and optimize treatment.  The Sonata System provides incision-free transcervical access for a uterus-preserving fibroid treatment.  This intrauterine approach is designed to avoid the peritoneal cavity.  Most side effects are typically minor and temporary.  The Sonata System is CE marked and is approved for sale in the European Union, the United Kingdom, and the United States.

About Gynesonics

Gynesonics is a women’s healthcare company focused on advancing women’s health, by developing minimally invasive, incision-free, uterus-preserving, transcervical technologies for diagnostic and therapeutic applications.  Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids.  Gynesonics headquarters is in Redwood City, CA.  For more information, go to www.gynesonics.com.

# # #

Company Contact:

Kelly Petrucci, Vice President of Healthcare Economics and Market Access, Gynesonics, kpetrucci@gynesonics.com

Media Contact:

David Gutierrez, Dresner Corporate Services, dgutierrez@dresnerco.com, (312) 780-7204

 

 

Filed Under: Press Releases

Footer

  • Privacy Policy
  • Terms of Use
  • Patents
  • Safety Information

© Copyright 2023 Gynesonics · All Rights Reserved · WS 05198 Rev. J

This website uses cookies to provide you with the best browsing experience.

Find out more or adjust your settings.

Gynesonics
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

Show details
Name Provider Purpose Expiration
moove_gdpr_popup Gynesonics via Moove GDPR Plugin This is used to save your cookie settings for this website. 12 months
__cf_bm Cloudflare The __cf_bm cookie is a cookie necessary to support Cloudflare Bot Management. As part of their bot management service, this cookie helps manage incoming traffic that matches criteria associated with bots. Cookie is set on websites using Cloudfare and it is related to rate limiting policies. less than 12m
Analytics Cookies

This website uses analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Show details
Name Provider Purpose Expiration
_ga, _gat, _gid, _ga_* Google Analytics These cookies enable analytics features in our suite (e.g., distinguish users, remember traffic information, and determine the start and end of a session). They are set for analytics measures on our website. We can take a timestamp of your website visit, track the source (e.g. search engine) you used to access our website, and the number of times you visit our website. 1-12 months
_gcl_au, _gat_gtag_UA_* Google Tag Manager These cookies helps us to enable functional requests on our website, such as the communications between our website and resources such as style, fonts, and images. As a cookie related to our Tag Manager, it collects your interaction with our resources (e.g. clicks and views) to help us understand your behavior on our website as well as to improve our aggregated analysis from interactions and campaigns. 1-12 months